Part of a comprehensive analysis of the Human Biomedical Research Act 2015
All Parts in This Series
Understanding Consent Provisions under the Human Biomedical Research Act 2015: A Case-Specific Analysis
The Human Biomedical Research Act 2015 (HBRA) establishes a comprehensive legal framework governing biomedical research in Singapore, with a particular emphasis on the ethical procurement of consent. This analysis focuses on Part 3 of the Act, which details the consent requirements essential for lawful biomedical research involving human subjects or tissue donors. The provisions ensure respect for individual autonomy, protect vulnerable populations, and maintain public trust in biomedical research.
Section 6: The Cornerstone of Consent Requirements
Section 6 of the HBRA sets out the fundamental requirements for obtaining "appropriate consent" for biomedical research. It mandates that consent must be:
"Any appropriate consent must for the purposes of this Act be obtained — (a) in writing; (b) from the research subject or tissue donor personally or otherwise obtained in accordance with section 7, 8, 9, 10 or 11, as the case may be; (c) after the information referred to in section 12 has been provided and explained to the research subject or tissue donor or the persons authorised to give consent on the subject’s or donor’s behalf under this Part, as the case may be; and (d) in the presence of a prescribed witness and in accordance with such other procedures and requirements as may be prescribed." — Section 6, Human Biomedical Research Act 2015
Verify Section 6 in source document →
This provision exists to ensure that consent is informed, voluntary, and properly documented. The requirement for written consent (Section 6(a)) provides a clear record, reducing disputes about whether consent was obtained. Obtaining consent personally or through authorized representatives (Section 6(b)) respects the autonomy of the individual while accommodating situations where the subject cannot consent personally. The prerequisite that information be provided and explained (Section 6(c)) guarantees that consent is truly informed, addressing the ethical principle of respect for persons. Finally, the presence of a prescribed witness and adherence to procedural requirements (Section 6(d)) add safeguards against coercion or fraud.
Sections 7 to 11: Tailored Consent Procedures for Vulnerable Groups
Recognizing that not all research subjects or tissue donors can provide consent in the same manner, Sections 7 through 11 specify consent procedures for particular categories:
- Section 7: Adults lacking mental capacity
- Section 8: Minors
- Section 9: Tissue donors lacking capacity
- Section 10: Minors donating tissue
- Section 11: Deceased persons
These provisions exist to protect vulnerable populations who may not be able to provide informed consent personally. For example, Section 7 allows consent to be obtained from legally authorized representatives for adults lacking mental capacity, ensuring that research participation is ethically permissible and legally valid. Similarly, Sections 8 and 10 regulate consent involving minors, balancing the need for research with the protection of children’s rights. Section 11 addresses consent related to deceased persons, respecting post-mortem autonomy and ethical considerations surrounding tissue use.
Sections 9(3) and 10(3) further provide for situations where the requirement for consent may be waived under certain conditions:
"waived such requirement under section 37(3)." — Sections 9(3), 10(3), Human Biomedical Research Act 2015
Verify source in source document →
This cross-reference to Section 37(3) allows for flexibility in exceptional circumstances, such as when the research has significant potential benefits and obtaining consent is impracticable, while still maintaining ethical oversight.
Section 12: Ensuring Informed Consent through Disclosure
Section 12 mandates the provision and explanation of specific information to the research subject or tissue donor before consent is obtained. Although the exact details are not quoted here, the purpose of this section is to ensure that consent is truly informed by requiring disclosure of relevant information such as the nature, purpose, risks, benefits, and alternatives to the research.
This provision exists to uphold the ethical principle of autonomy by enabling individuals to make knowledgeable decisions about participation. It also serves to protect researchers and institutions by documenting that adequate information was provided.
Section 13: Institutional Review Board’s Power to Waive Consent
Section 13 empowers institutional review boards (IRBs) to waive certain consent requirements under specified conditions:
"waiver ... in such circumstances as are specified in Part 1 of the Fifth Schedule;" — Section 13(1)(a), Human Biomedical Research Act 2015
Verify Section 13 in source document →
"does not affect a person’s duty to protect individually‑identifiable information from unauthorised disclosure under sections 29 and 39 or imposed by law;" — Section 13(3)(b), Human Biomedical Research Act 2015
Verify Section 13 in source document →
The existence of this provision acknowledges that in some research contexts, obtaining consent may be impracticable or may compromise the research’s validity. For example, retrospective studies using anonymized data may qualify for a waiver. However, the provision simultaneously emphasizes the continued obligation to protect privacy and confidentiality, as outlined in Sections 29 and 39, ensuring that ethical standards are not compromised.
Section 14: Right to Withdraw Consent
Section 14 provides research subjects or tissue donors the right to withdraw their consent at any time:
"The research subject or tissue donor may withdraw consent previously given under this Part." — Section 14, Human Biomedical Research Act 2015
Verify Section 14 in source document →
This provision exists to respect ongoing autonomy and control over participation in research. It recognizes that consent is not a one-time event but a continuing process. Withdrawal rights protect participants from feeling trapped or coerced and uphold ethical standards of voluntary participation.
Cross-References and Their Significance
The consent provisions in Part 3 of the HBRA are intricately linked with other sections and schedules within the Act, creating a cohesive regulatory framework:
- Sections 7 to 11: Detailed consent procedures for special populations referenced in Section 6 to clarify who may provide consent and under what circumstances.
- Section 12: Information disclosure requirements that precede consent.
- Section 13: IRB’s authority to waive consent requirements under specified conditions.
- Sections 29 and 39: Obligations to protect individually-identifiable information, ensuring confidentiality even when consent is waived.
- Section 37(3): Grounds for waiver of consent for therapeutic or diagnostic purposes, referenced in Sections 9(3) and 10(3).
- Fifth Schedule: Specifies circumstances under which consent may be waived, guiding IRBs in their decisions.
These cross-references exist to ensure that consent is not considered in isolation but as part of a broader ethical and legal framework that balances research advancement with individual rights and protections.
Absence of Explicit Definitions and Penalties in Part 3
It is notable that Part 3 CONSENT does not contain explicit definitions or specify penalties for non-compliance. This design likely reflects the Act’s structure, where definitions are centralized in earlier parts for clarity and penalties are addressed in separate enforcement provisions. The absence of penalties within Part 3 underscores that consent provisions are primarily ethical and procedural safeguards, with enforcement mechanisms located elsewhere in the Act.
"(No explicit definitions provided in Part 3 CONSENT.)" — Human Biomedical Research Act 2015
Verify source in source document →
"(No penalties specified in Part 3 CONSENT.)" — Human Biomedical Research Act 2015
Verify source in source document →
Conclusion
The consent provisions under the Human Biomedical Research Act 2015 are foundational to ethical biomedical research in Singapore. Section 6 establishes rigorous standards for obtaining consent, ensuring it is informed, voluntary, and properly documented. Sections 7 to 11 provide tailored procedures for vulnerable groups, reflecting a nuanced approach to autonomy and protection. Section 12 guarantees that consent is based on comprehensive information, while Section 13 allows for ethical flexibility through IRB waivers. Section 14 safeguards ongoing autonomy by permitting withdrawal of consent.
Collectively, these provisions embody the ethical principles of respect for persons, beneficence, and justice, while balancing the practical needs of biomedical research. The cross-references to other parts of the Act ensure a holistic regulatory environment that protects research subjects and tissue donors without unduly hindering scientific progress.
Sections Covered in This Analysis
- Section 6
- Sections 7 to 11
- Section 12
- Section 13
- Section 14
- Sections 29 and 39 (cross-referenced)
- Section 37(3) (cross-referenced)
- Fifth Schedule (cross-referenced)
Source Documents
For the authoritative text, consult SSO.